Positive Data on CYTK’s Tirasemtiv – Analyst Blog

By | November 27, 2012
0 Comment

Cytokinetics Inc. ( CYTK ) recently announced positive results on tirasemtiv from the phase IIa “Evidence of Effect” study which was conducted in patients suffering from

Read More:
Positive Data on CYTK’s Tirasemtiv – Analyst Blog

Related posts:

  1. Data from Roche’s Perjeta Study – Analyst Blog
  2. Phase III Data on Novartis’ RLX030 – Analyst Blog
  3. Encouraging Data on Glaxo’s Drug – Analyst Blog
  4. Positive Data on Sanofi’s Aubagio – Analyst Blog